Anti-Infectives - Global Strategic Business Report

The global market for Anti-Infectives is estimated at US$151.8 Billion in 2023 and is projected to reach US$231.3 Billion by 2030, growing at a CAGR of 6.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the anti-infectives market is driven by several factors. Technological advancements in drug discovery and development, such as high-throughput screening, artificial intelligence, and genomic studies, have accelerated the identification of potential anti-infective agents. These technologies allow for more precise targeting of pathogens, improving drug efficacy and reducing the likelihood of resistance development. The rising prevalence of chronic diseases and immunocompromised conditions, such as cancer, diabetes, and HIV, which increase susceptibility to infections, has heightened the demand for effective anti-infective therapies. Consumer behavior also plays a significant role, with increasing awareness and a proactive approach towards health and wellness contributing to market expansion. The expansion of healthcare infrastructure in emerging markets and improved access to healthcare services has further boosted the consumption of anti-infectives. Regulatory incentives, such as fast-track approvals and funding for antimicrobial resistance research, support the growth of this market. Collaborations between pharmaceutical companies, academic institutions, and government bodies are fostering innovation and development in the field, ensuring a continuous pipeline of new and effective anti-infective agents. Additionally, public-private partnerships and global health initiatives are crucial in addressing the unmet needs in the anti-infectives market, promoting the development and distribution of essential medicines to combat infectious diseases worldwide.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Anti-Viral Drugs segment, which is expected to reach US$117.1 Billion by 2030 with a CAGR of a 7.3%. The Anti-Fungal Drugs segment is also set to grow at 4.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $39.4 Billion in 2023, and China, forecasted to grow at an impressive 10.1% CAGR to reach $57.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Anti-Infectives Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Anti-Infectives Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Anti-Infectives Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Allergan PLC, Bayer AG, Bristol-Myers Squibb Company, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 17 Featured):

• Allergan PLC
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi